Search research articles
Contact Us
Filters
Showing results (221-230 of 435) with videos related to
Page
of 44
Sort By:
Arthritis Research & Therapy
|
June 9, 2018
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
Iain B McInnes, Philip J Mease, Georg Schett, et al.
Expert Review of Molecular Diagnostics
|
October 28, 2022
Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis
Jeffrey R Curtis, Vibeke Strand, Steven Golombek, et al.
Arthritis Care & Research
|
November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
Tore K Kvien, Philip G Conaghan, Laure Gossec, et al.
Expert Review of Molecular Diagnostics
|
December 23, 2021
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
Vibeke Strand, Stanley B Cohen, Jeffrey R Curtis, et al.
BMC Rheumatology
|
September 20, 2021
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
Atul A Deodhar, Philip J Mease, Proton Rahman, et al.
The Journal of Rheumatology
|
March 16, 2021
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting
Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, et al.
The Journal of Rheumatology
|
February 3, 2011
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis
Mark C Genovese, Stanley B Cohen, David Wofsy, et al.
Annals of the Rheumatic Diseases
|
March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
Vibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Arthritis and Rheumatism
|
April 16, 2002
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion
Désirée van der Heijde, Lee Simon, Josef Smolen, et al.
The Journal of Rheumatology
|
September 10, 2009
Measuring worker productivity: frameworks and measures
Dorcas Beaton, Claire Bombardier, Reuben Escorpizo, et al.
Page
of 44
Search research articles
Search
Showing results (221-230 of 435) with videos related to
Sort By:
Page
of 44
Arthritis Research & Therapy
|
June 9, 2018
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
Iain B McInnes, Philip J Mease, Georg Schett, et al.
Expert Review of Molecular Diagnostics
|
October 28, 2022
Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis
Jeffrey R Curtis, Vibeke Strand, Steven Golombek, et al.
Arthritis Care & Research
|
November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
Tore K Kvien, Philip G Conaghan, Laure Gossec, et al.
Expert Review of Molecular Diagnostics
|
December 23, 2021
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
Vibeke Strand, Stanley B Cohen, Jeffrey R Curtis, et al.
BMC Rheumatology
|
September 20, 2021
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
Atul A Deodhar, Philip J Mease, Proton Rahman, et al.
The Journal of Rheumatology
|
March 16, 2021
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting
Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, et al.
The Journal of Rheumatology
|
February 3, 2011
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis
Mark C Genovese, Stanley B Cohen, David Wofsy, et al.
Annals of the Rheumatic Diseases
|
March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
Vibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Arthritis and Rheumatism
|
April 16, 2002
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion
Désirée van der Heijde, Lee Simon, Josef Smolen, et al.
The Journal of Rheumatology
|
September 10, 2009
Measuring worker productivity: frameworks and measures
Dorcas Beaton, Claire Bombardier, Reuben Escorpizo, et al.
Page
of 44